Orforglipron: difference between revisions
Diff·revision 11 → 12·09:05, 5 May 2025
Difference between revision 11 and revision 12 of Orforglipron. 1 line changed; the page grew by 40 bytes.
| Revision 11 — 17:50, 14 Apr 2025 TimelineTiernan (talk) split §Pharmacology into receptor binding and downstream signalling 4,465 bytes +300 | Revision 12 — 09:05, 5 May 2025 LiraLotte (talk) label the animal data as animal data in the sentence, not only in the section heading 4,505 bytes +40 | ||
|---|---|---|---|
| 11 | | Compare = [[Oral semaglutide]], ≈0.4–1% with fasting conditions | 11 | | Compare = [[Oral semaglutide]], ≈0.4–1% with fasting conditions |
| 12 | }} | 12 | }} |
| + | 13 | {{medical|talk=Investigational status}} | |
| 13 | 14 | ||
| 14 | '''Orforglipron''' (development code '''LY3502970''') is an investigational orally administered non-peptide agonist of the [[GLP-1 receptor]]. It is not a peptide and is not subject to proteolysis, so it requires neither an absorption enhancer nor the strict fasting conditions that govern [[Oral semaglutide|oral semaglutide]].{{r|kawai2020}} | 15 | '''Orforglipron''' (development code '''LY3502970''') is an investigational orally administered non-peptide agonist of the [[GLP-1 receptor]]. It is not a peptide and is not subject to proteolysis, so it requires neither an absorption enhancer nor the strict fasting conditions that govern [[Oral semaglutide|oral semaglutide]].{{r|kawai2020}} |